Table 1.
Patients’ characteristics
| Median age (years) | 89.5 (66–98) |
| Gender | |
| Female | 4 (33.3%) |
| Male | 8 (66.7%) |
| Histotype | |
| Squamous cell carcinoma | 8 (34.8%) |
| Basal cell carcinoma | 15 (65.2%) |
| Stage | |
| T1 tumors (clinically evaluated) | 9 (39.1%) |
| T2 tumors (clinically evaluated) | 13 (56.6%) |
| T4 tumors (radiologically confirmed) | 1 (4.3%) |
| Tumor site | |
| Nose | 2 (8.7%) |
| Zygomatic area | 5 (21.7%) |
| Eyelid-periorbital area | 1 (4.3%) |
| Ear, pre- and retroauricolar region | 5 (21.7%) |
| Cheek | 5 (21.7%) |
| Forehead-temples | 3 (13%) |
| Vertex | 2 (8.7%) |
| Acute skin toxicity sec. CTC AE | |
| G1 | 12 (52.2%) |
| G2 | 8 (34.8%) |
| G3 | 3 (13%) |
| G4 | 0 |
| Response | |
| Complete responses | 22 (95.7%) |
| Partial responses | 1 (4.3%) |
CTCAE — Common Terminology Criteria for Adverse Events